Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: HIMA staff changes

This article was originally published in The Gray Sheet

Executive Summary

HIMA staff changes: Former Department of Commerce International Trade Specialist Paul Barry assumes position as director of global strategy and analysis at the Health Industry Manufacturers Association, effective Jan. 2. Barry replaces Terri Zavada, who left HIMA Dec. 5 to establish Zavada International, a consulting firm dealing with international medical device trade issues with an emphasis on Asia. Barry has worked extensively with HIMA in the past on device issues, particularly on matters related to reimbursement in Japan, in the context of the Pharmaceutical Products Market-Oriented Sector-Selective (MOSS) trade talks. Yet to be named is a replacement for HIMA Associate VP-Public Affairs Holly Glass, who left the trade association Sept. 15 to establish Glass Public Affairs, a device public relations firm. HIMA Manager of Government Affairs Jeanne Wilton also is leaving the association to enter consulting; a replacement has not yet been designated...

You may also be interested in...

Chloroquine ‘Approval’ For COVID-19 And The US FDA’s New Reality

Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.

Biopharma, Payers Seek National Guidelines For Prescribing Potential COVID-19 Drugs

Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.

Becton Dickinson, BioMedomics Collaborate On Rapid Serology COVID-19 Test

BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts